CF
HOWL icon

Corebridge Financial’s Werewolf Therapeutics HOWL Stock Holding History

Corebridge Financial’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,355
Closed -$14.9K – 1238
2025
Q1 		$14.9K Buy
15,355
+199
+1% +$261 ﹤0.01% 2942
2024
Q4 		$22.4K Sell
15,156
-1,144
-7% -$2.33K ﹤0.01% 2951
2024
Q3 		$34.6K Sell
16,300
-101
-0.6% -$230 ﹤0.01% 2935
2024
Q2 		$40.2K Buy
+16,401
New +$78.8K ﹤0.01% 2929

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Corebridge Financial's HOWL Position: Q2 2025 in Review

Corebridge Financial sold out of Werewolf Therapeutics (HOWL) in Q2 2025, closing a stake of 15,355 shares — an estimated $14.9K sold.

Corebridge Financial first reported a position in HOWL in Q2 2024 and held it in 4 quarters. The position peaked at $40.2K in Q2 2024. 65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Corebridge Financial reported no remaining Werewolf Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 15,355 Werewolf Therapeutics shares in Q2 2025, an estimated $14.9K.
  • Corebridge Financial first reported a position in Werewolf Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Werewolf Therapeutics position peaked at $40.2K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.